Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 2 Medications in patients with orthostatic hypotension and CART therapy

From: CD-19 CART therapy and orthostatic hypotension: a single center retrospective cohort study

 

Cohort (%)

No orthostatic hypotension (%)

Orthostatic hypotension (%)

p-value

n

42

9

33

 

Pre-CART

  Beta blocker

7 (16.7)

2 (22.2)

5 (15.2)

0.631

  ACEI/ARB

6 (14.3)

2 (22.2)

4 (12.1)

0.593

  CCB

4 (9.5)

0 (0.0)

4 (12.1)

0.561

  Thiazide diuretic

3 (7.1)

1 (11.1)

2 (6.1)

0.525

  Loop diuretic

2 (4.8)

1 (11.1)

1 (3.0)

0.387

  Arterial vasodilator

1 (2.4)

0 (0.0)

1 (3.0)

1

  Anti-depressants

6 (14.3)

1 (11.1)

5 (15.2)

1

  Neuroleptics

4 (9.5)

1 (11.1)

3 (9.1)

1

  Alpha-1 blockers

1 (2.4)

0 (0.0)

1 (3.0)

1

  Midodrine

0 (0.0)

0 (0.0)

0 (0.0)

1

  Fludrocortisone

1 (2.4)

0 (0.0)

1 (3.0)

1

CART discharge

  Beta blocker

9 (21.4)

3 (33.3)

6 (18.2)

0.375

  ACEI/ARB

2 (4.8)

0 (0.0)

2 (6.1)

1

  CCB

4 (9.5)

0 (0.0)

4 (12.1)

0.561

  Thiazide diuretic

1 (2.4)

0 (0.0)

1 (3.0)

1

  Loop diuretic

1 (2.4)

0 (0.0)

1 (3.0)

1

  Arterial vasodilator

1 (2.4)

0 (0.0)

1 (3.0)

1

  Anti-depressants

10 (23.8)

1 (11.1)

9 (27.3)

0.416

  Neuroleptics

2 (4.8)

1 (11.1)

1 (3.0)

0.387

  Alpha-1 blockers

4 (9.5)

0 (0.0)

4 (12.1)

0.561

  Midodrine

2 (4.8)

0 (0.0)

2 (6.1)

1

  Fludrocortisone

2 (4.8)

0 (0.0)

2 (6.1)

1

1 month post-CART

  Beta blocker

6 (14.3)

2 (22.2)

4 (12.1)

0.593

  ACEI/ARB

1 (2.4)

0 (0.0)

1 (3.0)

1

  CCB

3 (7.1)

0 (0.0)

3 (9.1)

1

  Thiazide diuretic

0 (0.0)

0 (0.0)

0 (0.0)

1

  Loop diuretic

1 (2.4)

0 (0.0)

1 (3.0)

1

  Arterial vasodilator

0 (0.0)

0 (0.0)

0 (0.0)

1

  Anti-depressants

9 (21.4)

1 (11.1)

8 (24.2)

0.655

  Neuroleptics

3 (7.1)

1 (11.1)

2 (6.1)

0.525

  Alpha-1 blockers

4 (9.5)

0 (0.0)

4 (12.1)

0.561

  Midodrine

6 (14.3)

0 (0.0)

6 (18.2)

0.312

  Fludrocortisone

5 (11.9)

0 (0.0)

5 (15.2)

0.567

3 months post-CART

  Beta blocker

7 (16.7)

3 (33.3)

4 (12.1)

0.155

  ACEI/ARB

2 (4.8)

0 (0.0)

2 (6.1)

1

  CCB

2 (4.8)

0 (0.0)

2 (6.1)

1

  Thiazide diuretic

0 (0.0)

0 (0.0)

0 (0.0)

1

  Loop diuretic

1 (2.4)

0 (0.0)

1 (3.0)

1

  Arterial vasodilator

0 (0.0)

0 (0.0)

0 (0.0)

1

  Anti-depressants

10 (23.8)

1 (11.1)

9 (27.3)

0.416

  Neuroleptics

3 (7.1)

0 (0.0)

3 (9.1)

1

  Alpha-1 blockers

1 (2.4)

0 (0.0)

1 (3.0)

1

  Midodrine

4 (9.5)

0 (0.0)

4 (12.1)

0.561

  Fludrocortisone

7 (16.7)

0 (0.0)

7 (21.2)

0.314

  1. ACEI ACE inhibitor, ARB Angiotensin receptor blocker, CART Chimeric antigen receptor T-cell, CCB Calcium channel blocker
  2. Bolded text represents subheadings
Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us